Importantly, the induction of this functional immune response characterized by activated T cells expressing PD-1mid and PD-L1 expression in the tumor microenvironment provided the foundation for synergistic therapy by combination with PD-1 axis blockade. This evidence concerns the gene PDCD1 and neoplasm.